Skip to main content

Table 2 Demographic and clinical characteristics of study groups for the analysis of gastric acid and the analysis of permeability, translocation and immune activation

From: Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial

 

Gastric acid sub-group

Translocation sub-group

 

MM

Placebo

MM

Placebo

 

(n = 100)

(n = 103)

(n = 38)

(n = 49)

Age (yrs) (median, 5th/95th centiles)

31 (19-65)

36 (20-62)

41 (19-56)

29 (18-51)

Sex Male

35

48

8

14

   Female

65

55

30

35

BMI (kg/m2) (median, 5th/95th centiles)

21.3 (17.9-31.7)

21.9 (17.7-31.6)

22.1 (18.3-36.3)

23.2 (18.0-41.6)

MUAC (cm) (median, 5th/95th centiles)

28.0 (24.0-38.0)

27.4 (23.0-34.3)

26.0 (22.5-37.0)

26.8 (21.9-38.2)

HIV positive

40 of 97 tested

44 of 101 tested

5 of 29 tested

12 of 46 tested

CD4 count (median, 5th/95th centiles)

382 (68-716)

349 (161-659)

362 (331-634)

466 (190-936)

CD4 count < 200 cells/μL

7/40

4/44

0/5

2/12

  1. P values are not shown: none of the comparisons between MM and placebo were significant